Aurobindo named in a lawsuit for selling adulterated irbesartan products

In October, Aurobindo Pharma announced a voluntary recall of 22 batches of irbesartan due to the detection of trace amounts of NDEA

Hyderabad-based drug major Aurobindo Pharma Limited has been named in a class action lawsuit in the US for contamination of its irbesartan active ingredient (API) used in the treatment of high blood pressure.

The lawsuit was filed in the Federal Court of Florida against Aurobindo Pharma and also the US-based pharma company ScieGen Pharmaceuticals, which used Aurobindo's irbesartan API to make its blood pressure lowering product, besides the distributor Westminster Pharmaceuticals and the US retail supply chain Walmart.

Aurobindo scrip lost as much as Rs 22 or down close to 3 per cent on Tuesday after touching a new 52-week